News articles about Sorrento Therapeutics (NASDAQ:SRNE) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sorrento Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.3309596008766 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Unusual Volume Spotlight – Sorrento Therapeutics, Inc. (SRNE) – Wall Street Morning (wallstreetmorning.com)
- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) – Hot Stock in the Spotlight – Nasdaq Journal (nasdaqjournal.com)
- Facts About In Play Stocks: Sorrento Therapeutics Inc (NASDAQ: SRNE) – Alpha Beta Stock (alphabetastock.com)
- Sorrento Therapeutics CEO Dr. Ji to Present at Roth Capital … – GlobeNewswire (press release) (globenewswire.com)
- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) – An Eye on Price to Earnings Ratio – Nasdaq Journal (nasdaqjournal.com)
Several research firms recently weighed in on SRNE. HC Wainwright set a $38.00 price target on shares of Sorrento Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 6th. BidaskClub lowered shares of Sorrento Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 6th. Oppenheimer restated a “buy” rating and set a $9.00 price target on shares of Sorrento Therapeutics in a research report on Friday, January 19th. Finally, ValuEngine upgraded shares of Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $15.00.
In other Sorrento Therapeutics news, major shareholder Abg Management Ltd sold 150,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $7.19, for a total transaction of $1,078,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Pacific Medtech (Bvi) Ltd Asia sold 684,288 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $7.56, for a total transaction of $5,173,217.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,215,009 shares of company stock worth $9,185,885. Insiders own 5.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/03/14/sorrento-therapeutics-srne-receives-news-sentiment-score-of-0-16/2027246.html.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.